|
|
Post by mnholdem on Jul 10, 2018 12:08:33 GMT -5
Q&A: New developments with inhalable medicines
By Tim Sandle 20 hours ago in [July 9, 2018] in Health.
Excerpts:
Digital Journal caught up with Castagna to discuss his company’s novel treatments.
Digital Journal: What is the extent of diabetes in the developed world?
Michael Castagna: Unfortunately, diabetes is increasing in the developed world. According to the CDC, 30.3 million U.S. adults have diabetes, and 1 in 4 are unaware that they have it. Diabetes is the seventh leading cause of death in the U.S., and is the No. 1 cause of kidney failure, lower-limb amputations and adult-onset blindness. Over the last two decades, the number of adults diabetes with diabetes has more than tripled.
DJ: Why did you decide to develop an easier to administer form of diabetes treatment?
Castagna: Al Mann’s vision was to make the treatment of diabetes easier for patients. He assembled the technology to improve upon currently available insulin delivery options. Afrezza offers patients a method of delivering insulin for mealtime glucose control that is not injected, and due to the way insulin is distributed through the lungs, it has an unmatched time action profile for both how quickly the insulin can work and how long a dose of insulin may stay in the system.
DJ: What has been the response from the medical community?
Castagna: The reaction has been very positive from many medical professionals. We’re extremely excited as more and more of those in the medical community are realizing the advancement we’ve made with inhalable insulin.
For others, like any new innovation (consider those who took a while to move from the flip phone to the iPhone), it can take some time to adopt the very latest. We find that most of the time, once medical professionals learn about Afrezza and start providing it to patients, they continue to prescribe it.
Also, we continue to work to educate doctors and help them understand that the benefits of this product go beyond inhalation; and that the greatest benefits revolve around the rapid-acting nature of our inhaled insulin at mealtime.
Read more: www.digitaljournal.com/life/health/q-a-new-developments-with-inhalable-medicines/article/526679#ixzz5Ks8kvslR
|
|
|
|
Post by mytakeonit on Jul 10, 2018 13:12:42 GMT -5
Oh crap ... Warren Buffet and I are the last two people on this planet with a flip phone !!! He has a black one and I have a white one.
Yes, it is true ... just read it. It's all in black and white.
|
|
|
|
Post by mango on Jul 10, 2018 13:31:04 GMT -5
DJ: What do you plan to work on next?
Castagna: We believe there are significant opportunities to bringing what we’ve done with inhaled insulin for diabetes to other chronic conditions. We have several in our product development pipeline.
For example, we just announced the we completed our Phase 1 Trial of Inhaled Medicine for Pulmonary Arterial Hypertension. TreT is proposed as a drug-device combination product for the treatment of patients with pulmonary arterial hypertension (PAH), utilizing a small, portable, breath-powered inhaler that is intended to simplify drug dosing.
--------------------------------------------------------------------------------
I wonder what the MannKind inhaler for PAH looks like?
|
|
|
|
Post by tomtabb on Jul 10, 2018 15:23:22 GMT -5
DJ: What do you plan to work on next?Castagna: We believe there are significant opportunities to bringing what we’ve done with inhaled insulin for diabetes to other chronic conditions. We have several in our product development pipeline.
For example, we just announced the we completed our Phase 1 Trial of Inhaled Medicine for Pulmonary Arterial Hypertension. TreT is proposed as a drug-device combination product for the treatment of patients with pulmonary arterial hypertension (PAH), utilizing a small, portable, breath-powered inhaler that is intended to simplify drug dosing.-------------------------------------------------------------------------------- I wonder what the MannKind inhaler for PAH looks like? What's the next step for the PAH drug? |
|
|
|
Post by mango on Jul 10, 2018 15:57:41 GMT -5
DJ: What do you plan to work on next?Castagna: We believe there are significant opportunities to bringing what we’ve done with inhaled insulin for diabetes to other chronic conditions. We have several in our product development pipeline.
For example, we just announced the we completed our Phase 1 Trial of Inhaled Medicine for Pulmonary Arterial Hypertension. TreT is proposed as a drug-device combination product for the treatment of patients with pulmonary arterial hypertension (PAH), utilizing a small, portable, breath-powered inhaler that is intended to simplify drug dosing.-------------------------------------------------------------------------------- I wonder what the MannKind inhaler for PAH looks like? What's the next step for the PAH drug? phase 3 |
|
|
|
Post by tomtabb on Jul 11, 2018 9:59:00 GMT -5
What's the next step for the PAH drug? phase 3 Thanks. Do they simply apply to do the phase 3 or do they need to have discussions with the FDA first? What kind of timeline are we looking at? Also, are there any patent issues that might need to be resolved first? United Theraputics appears to be pretty aggressive in protecting their franchise. |
|
